Corbus Pharmaceuticals Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Corbus Pharmaceuticals details its 2024 financial performance and outlines progress in its oncology and obesity drug development programs.
NASDAQ
10-K/A: Corbus Pharmaceuticals Amends Annual Report to Include Omitted Executive Compensation Details
Corbus Pharmaceuticals has filed an amendment to its annual report to include previously omitted information regarding executive compensation and related certifications.
NASDAQ
Corbus Pharmaceuticals' 2023 annual report highlights progress in its oncology and obesity pipelines, including clinical trial advancements and regulatory clearances, alongside significant financial losses.